Search

Your search keyword '"Bradbury, Charlotte"' showing total 274 results

Search Constraints

Start Over You searched for: Author "Bradbury, Charlotte" Remove constraint Author: "Bradbury, Charlotte"
274 results on '"Bradbury, Charlotte"'

Search Results

1. Simvastatin in Critically Ill Patients with Covid-19.

3. Heparin Dose Intensity and Organ Support-Free Days in Patients Hospitalized for COVID-19

4. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

5. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

6. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.

7. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.

8. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial

9. Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial

11. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.

12. ISTH guidelines for antithrombotic treatment in COVID‐19

13. Real‐world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study

14. Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis

15. Heparin Dose Intensity and Organ Support-Free Days in Patients Hospitalized for COVID-19

16. Coproducing Health Information Materials With Young People: Reflections and Lessons Learned.

20. PB2612: UNITED KINGDOM RETROSPECTIVE OBSERVATIONAL STUDY OF ROMIPLOSTIM AND OTHER TREATMENTS IN EARLY IMMUNE THROMBOCYTOPENIA

23. Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: a multicentre observational study

24. Systemic immunosuppression depletes peripheral blood regulatory B cells in patients with immune thrombocytopenia.

25. Response to Knight and Nelson‐Piercy ‘Clarity of guidelines concerning the care of pregnant women is lost by the use of de‐sexed language’

26. Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial

27. Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19

28. A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK

29. Retrospective, Observational, Multicenter Study Assessing the Thrombopoietin Receptor Agonist (TPO-RA) Romiplostim and Other Treatments for Patients with Newly Diagnosed or Persistent Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice in the United Kingdom (UK)

30. A HaemSTAR-led, UK-wide 'flash-mob’ audit of ­intravenous immunoglobulin use in immune ­thrombocytopenia

33. British Society for Haematology guideline for anticoagulant management of pregnant individuals with mechanical heart valves.

35. Long-term risk of major bleeding after discontinuing anticoagulation for unprovoked venous thromboembolism: a systematic review and meta-analysis

36. Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19.

37. Long-term Risk of Recurrent Venous Thromboembolism Among Patients Receiving Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism

38. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial

39. Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.

40. Long-Term Risk of Major Bleeding after Discontinuing Anticoagulation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis

41. How Effective Are the Immunosuppressive Therapies Rituximab and Mycophenolate Mofetil in Immune Thrombocytopenia? Real World Evidence from the UK ITP Registry

43. Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia

44. Incidence of adult primary immune thrombocytopenia in England—An update.

46. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary report

47. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19 : a meta-analysis

48. Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis

Catalog

Books, media, physical & digital resources